Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFS NASDAQ:CLPT NYSE:ENOV NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$26.10-1.9%$22.77$17.86▼$29.62$1.30B2776,891 shs695,468 shsCLPTClearPoint Neuro$13.44-2.9%$11.50$8.27▼$30.10$415.06M1.31553,469 shs448,348 shsENOVEnovis$21.70+2.7%$24.03$20.55▼$36.82$1.22B1.381.04 million shs907,673 shsTNDMTandem Diabetes Care$16.60+5.1%$17.75$9.98▼$29.65$1.08B1.582.91 million shs1.93 million shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions-0.23%-1.81%+25.29%+44.88%+12.05%CLPTClearPoint Neuro+0.65%-3.35%+9.49%+28.27%+7.70%ENOVEnovis-3.67%-7.22%-18.44%-7.75%-36.40%TNDMTandem Diabetes Care-2.65%-18.77%+7.56%-26.82%-26.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$26.10-1.9%$22.77$17.86▼$29.62$1.30B2776,891 shs695,468 shsCLPTClearPoint Neuro$13.44-2.9%$11.50$8.27▼$30.10$415.06M1.31553,469 shs448,348 shsENOVEnovis$21.70+2.7%$24.03$20.55▼$36.82$1.22B1.381.04 million shs907,673 shsTNDMTandem Diabetes Care$16.60+5.1%$17.75$9.98▼$29.65$1.08B1.582.91 million shs1.93 million shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions-0.23%-1.81%+25.29%+44.88%+12.05%CLPTClearPoint Neuro+0.65%-3.35%+9.49%+28.27%+7.70%ENOVEnovis-3.67%-7.22%-18.44%-7.75%-36.40%TNDMTandem Diabetes Care-2.65%-18.77%+7.56%-26.82%-26.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 2.40Hold$32.0022.61% UpsideCLPTClearPoint Neuro 2.33Hold$18.0033.93% UpsideENOVEnovis 2.67Moderate Buy$44.50105.09% UpsideTNDMTandem Diabetes Care 2.48Hold$29.8479.77% UpsideCurrent Analyst Ratings BreakdownLatest CLPT, ENOV, TNDM, and BLFS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026TNDMTandem Diabetes Care Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/10/2026TNDMTandem Diabetes Care Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/9/2026CLPTClearPoint Neuro Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$16.006/1/2026TNDMTandem Diabetes Care Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Overweight$21.00 ➝ $27.006/1/2026ENOVEnovis Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/28/2026TNDMTandem Diabetes Care CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$22.00 ➝ $17.005/27/2026TNDMTandem Diabetes Care The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$21.005/26/2026TNDMTandem Diabetes Care Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026ENOVEnovis BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$39.005/18/2026TNDMTandem Diabetes Care Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$35.00 ➝ $25.005/12/2026BLFSBioLife Solutions Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$96.21M13.25$0.22 per share116.17$7.72 per share3.38CLPTClearPoint Neuro$36.97M10.90N/AN/A$0.99 per share13.58ENOVEnovis$2.25B0.56$27.47 per share0.79$26.09 per share0.83TNDMTandem Diabetes Care$1.01B1.12N/AN/A$2.29 per share7.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$4.59M-$0.08N/A130.50N/A-2.80%1.81%1.65%8/6/2026 (Estimated)CLPTClearPoint Neuro-$25.54M-$1.01N/AN/AN/A-71.57%-140.96%-36.98%8/11/2026 (Estimated)ENOVEnovis-$1.18B-$19.886.255.45N/A-49.92%10.32%4.57%8/6/2026 (Estimated)TNDMTandem Diabetes Care-$204.71M-$1.40N/A415.00N/A-9.20%-53.88%-7.88%8/5/2026 (Estimated)Latest CLPT, ENOV, TNDM, and BLFS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026CLPTClearPoint Neuro-$0.28-$0.32-$0.04-$0.32$11.97 million$12.13 million5/7/2026Q1 2026BLFSBioLife Solutions$0.01$0.04+$0.03$0.02$25.66 million$27.50 million5/7/2026Q1 2026ENOVEnovis$0.82$0.89+$0.07-$0.15$572.02 million$589.15 million5/7/2026Q1 2026TNDMTandem Diabetes Care-$0.46-$0.30+$0.16-$0.30$240.41 million$247.22 million3/17/2026Q4 2025CLPTClearPoint Neuro-$0.22-$0.27-$0.05-$0.27$10.40 million$10.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/ACLPTClearPoint NeuroN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife SolutionsN/A7.305.50CLPTClearPoint Neuro2.635.794.88ENOVEnovis0.872.041.05TNDMTandem Diabetes Care4.543.583.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%CLPTClearPoint Neuro30.08%ENOVEnovis98.45%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%CLPTClearPoint Neuro6.94%ENOVEnovis2.90%TNDMTandem Diabetes Care2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44048.86 million47.78 millionOptionableCLPTClearPoint Neuro11029.99 million27.91 millionOptionableENOVEnovis7,80257.56 million55.89 millionOptionableTNDMTandem Diabetes Care2,50068.53 million67.09 millionOptionableCLPT, ENOV, TNDM, and BLFS HeadlinesRecent News About These CompaniesTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 10 at 2:28 AM | americanbankingnews.comTandem Diabetes: Neutral Stance Maintained as Mobi Tubeless Opportunity Balances Execution Risks; $25 Price Target UnchangedJune 9 at 6:30 AM | tipranks.comTandem Diabetes Care, Inc. (TNDM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comHow The Investment Story For Tandem Diabetes Care (TNDM) Is Evolving Without New Analyst TargetsJune 7, 2026 | finance.yahoo.comTandem insulin pumps cleared in EU for expanded indicationsJune 6, 2026 | seekingalpha.comWall Street Analysts See a 56.2% Upside in Tandem Diabetes Care (TNDM): Can the Stock Really Move This High?June 5, 2026 | zacks.comTandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During PregnancyJune 5, 2026 | businesswire.comReasons to Add Tandem Diabetes Stock to Your Portfolio Right NowJune 4, 2026 | zacks.com3 Stocks to Invest in as Broker Rating Upgrades Signal UpsideJune 4, 2026 | zacks.comTandem: Upgrading To Hold On A High-Stakes Pivot StoryJune 4, 2026 | seekingalpha.comWells Fargo Upgrade Highlights Tandem Diabetes Care Pharmacy And Pump ShiftJune 3, 2026 | finance.yahoo.comTandem Diabetes Valuation: Is 1.1x Sales a Buy?June 3, 2026 | zacks.comTNDM Stock: What to Know About Tandem's 2026 ResetJune 2, 2026 | zacks.comTandem Diabetes Care Inc (TNDM) Shares Surge 12.9% -- What GF Score of 62 Tells InvestorsMay 28, 2026 | gurufocus.comTandem Diabetes Care (TNDM) Is Up 16.7% After Beating Q3 Views And Reaffirming 2025 EBITDA Target – Has The Bull Case Changed?May 24, 2026 | finance.yahoo.comSilver Economy Investing: Why the Healthcare Giants Are in FocusMay 19, 2026 | zacks.comTandem Diabetes’s Q1 earnings call: Our top 5 analyst questionsMay 14, 2026 | msn.comTNDM stock down following Q1 earnings & revenue beat, gross margin upMay 14, 2026 | msn.comTNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin UpMay 14, 2026 | zacks.comTandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Alphabet's Googlebook Brings Gemini AI to PC HardwareBy Ryan Hasson | May 16, 2026CLPT, ENOV, TNDM, and BLFS Company DescriptionsBioLife Solutions NASDAQ:BLFS$26.10 -0.50 (-1.88%) Closing price 04:00 PM EasternExtended Trading$25.90 -0.20 (-0.77%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.ClearPoint Neuro NASDAQ:CLPT$13.44 -0.40 (-2.89%) Closing price 04:00 PM EasternExtended Trading$13.53 +0.09 (+0.64%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Enovis NYSE:ENOV$21.70 +0.58 (+2.74%) Closing price 03:59 PM EasternExtended Trading$21.80 +0.10 (+0.45%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.Tandem Diabetes Care NASDAQ:TNDM$16.60 +0.80 (+5.06%) Closing price 04:00 PM EasternExtended Trading$16.60 +0.00 (+0.03%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
